1
Return

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial

delete2026-08-06
delete0
PRE
AI
S
Scott T. Tagawa
O
Oliver Sartor
J
Josep M. Piulats
F
Fred Saad
K
Karim Fizazi
A
Alison Reid
H
Himisha Beltran
G
Gero Kramer
H
Hakim Mahammedi
M
Matthias Eiber
S
Shilpa Gupta
D
Daniel Castellano
R
Ralph Hauke
H
H. Kim
C
Cheol Kwak
S
See Tong Pang
P
Philippe Barthélémy
D
Dong Dai
J
Jae Lyun Lee
L
Luke Nordquist
DOI：10.1016/s0140-6736(26)01092-5delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
A contemporary standard of care for patients with metastatic androgen pathway modulator-naive/sensitive (APMN/S) prostate cancer (also known as metastatic hormone-sensitive prostate cancer) is androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI) until progression. PSMAddition aimed to evaluate the efficacy and safety of [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) combined with ADT plus ARPI in prostate-specific membrane antigen (PSMA)-positive metastatic APMN/S prostate cancer.

Journal

The Lancet cover
The Lancet
IF:
88.5
Papers:
5.4W
Citations:
34.8W

Organization

No organization information available
Cited Papers

Cited Papers

Citing Papers

Citing Papers